Lundbeck highly ranked by patient groups
10 March 2016
Worldwide survey places Lundbeck 3rd in corporate reputation among pharma companies.
The 2015 rating as 3rd best in corporate reputation is an improvement of two ranks compared to 2014.
PatientView, a research, publishing and consultancy group working to build bridges between health Non-Governmental Organizations worldwide, has today announced the results of its annual survey The Corporate Reputation of Pharma – The Patient Perspective in 2015.
Read the press release.
High ratings in patient centricity and useful products
In the survey, patient organizations were asked to evaluate the reputation of pharma companies in relation to aspects as patient centricity, patient information, patient safety, usefulness of products, transparency and integrity. Lundbeck’s increased ranking was particularly driven by higher ratings in aspects as providing high-quality information to patients, having products with a high level of usefulness, having an effective patient-centred strategy and for working transparently with external stakeholders.
“It’s great to see that we continue to mark ourselves as one of the industry leaders in building and maintaining valuable relationships with patients and patient advocacy groups. We are being recognized for key dimensions of our business, such as high-quality products and patient-centricity”, CEO Kåre Schultz comments.
Kåre Schultz continues: “We can be very proud about being rated as the 3rd best in corporate reputation. This ranking confirms our commitment to continue our work for psychiatric and neurological patients in 2016 through continuous engagement and activities with patient advocacy groups locally and globally”.